Skip to content

Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control

Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02362893
Acronym
DRIVE
Enrollment
20
Registered
2015-02-13
Start date
2015-04-30
Completion date
2018-12-31
Last updated
2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Adherence, Direct Observed Therapy (DOT), RCT

Brief summary

The purpose of the study is to access the change in mean daytime systolic blood pressure in participants with essential hypertension not adequately controlled (defined as mean systolic daytime ambulatory blood pressure ≥ 135 mmHg) and randomly assigned to either an intervention group with one-time only Direct Observed Therapy (DOT) immediately followed by ABPM or a control group with standard ABPM.

Detailed description

More than 1 billion people world wide suffer from hypertension (HT), leaving it the world´s top rank risk factor and contributor to global disease burden. Cardiac disease, stroke, kidney disease and dementia are diseases related to HT with high economic burden on societies and each year 9.4 million people die as a direct consequence of HT. Estimated \< 50 % of hypertensive patients adhere to preventive hypertensive medication after 1 year of treatment. Poor adherence to antihypertensive treatment have by many been explained partly by the silent nature of hypertension, the risk of side effects from antihypertensive medication, treatment expenditures and the patient health perspectives. In a randomized controlled trial design we plan to enrol 20 subjects, the limited number explained by the study being part of the initial planning of a larger scale trial organized by the research group, to invistigate the change in ambulatory bloodpressure with or with out Direct Observed Theraphy prior to meassurement, as a one-time-only medication adherence check.

Interventions

Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years and above * Residing in Oslo/Akershus * Ambulatory Systolic Daytime Blood Pressure ≥ 135 mmHg * ≥ 2 antihypertensive medications * Be able to read and write Norwegian

Exclusion criteria

* Critical illness, ongoing treatment * Known atrial fibrillation * Known heart valve stenosis * Myocardial infarction, angina pectoris or stroke the past 6 months * Known severe renal impairment (eGFR \< 30 ml/min/1.73 m2) * History of DOT prior to ABPM * Participation in other interventional study

Design outcomes

Primary

MeasureTime frame
Change in 24-hour ambulatory mean systolic daytime blood pressureMeasurement at follow-up visit 3 weeks ± 7 days relative to baseline.

Secondary

MeasureTime frame
Change in mean office systolic blood pressureMeasurement at follow-up visit 3 weeks ± 7 days relative to baseline.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026